RESEARCH TRIANGLE PARK, N.C. , Dec. 24, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT ® technology, today announced that it

Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA) Targeting Submission of NDA for LIQ861 in 1Q 2020 Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.

RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that third quarter 2019 financial results will be reported on Wednesday, November 13, 2019 .

RESEARCH TRIANGLE PARK, N.C. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin , Vice President of Global Commercial Development at

RESEARCH TRIANGLE PARK, N.C. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the

RESEARCH TRIANGLE PARK, N.C. , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Joanna Horobin , M.B., Ch.B., to the Company’s Board of Directors (the

RESEARCH TRIANGLE PARK, N.C. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the H.C.

RESEARCH TRIANGLE PARK, N.C. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the 2019

On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Aug.

RESEARCH TRIANGLE PARK, N.C. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology , today announced